



[www.eano.eu](http://www.eano.eu)



#EANO2024

University of Glasgow Photographic Unit

19<sup>TH</sup> MEETING & EDUCATIONAL DAY  
OF THE EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY

# EANO 2024

## GLASGOW, UNITED KINGDOM

**PROGRAMME**

OCT 17 - 20, 2024

SCOTTISH EVENT CAMPUS | SEC



Presidential Address	4
Board, Scientific Committee, Organisation	5
Programme Overview	6 - 9
Side Meetings	10
Poster Information	11
Save the Date EANO 2025	12
Corporate Symposia	13
Sponsors & Exhibitors	14
General Information	15 - 18
Networking Events	20 - 21
Floor Plans	22 - 24

The European Association of Neuro-Oncology gratefully acknowledges the support of the

**GLASGOW  
CONVENTION  
BUREAU**

**EANO 2024  
CONGRESS APP**

Everything important at a glance!

Download for free and put the congress in your pocket now!

Scan QR-Code:

Or search for „Floq by Conference Compass“ in the App Store:

Download on the App Store

GET IT ON Google Play

**floq**  
by Conference Compass

26 Aug 2024, 13:00  
Welcome to EANO 2024!  
This app provides all information to manage the congress:  
• Browse the programme by day or session type  
• Read abstracts and session descriptions  
• Add events, presentations and/or posters  
No other information required.  
Read more

Dear EANO members, colleagues and friends,

Welcome to the **19<sup>th</sup> Meeting of the European Association of Neuro-Oncology (EANO 2024)** and EANO's 30<sup>th</sup> anniversary celebrations in Glasgow. Glasgow is renowned for its vibrant, friendly atmosphere and its proximity to the natural beauty and grandeur of Scotland. During the meeting you will surely understand why the city has adopted 'People Make Glasgow' as its motto.

As usual, the annual EANO meeting will kick off with an **Educational Day on Thursday, October 17** and the **main programme will commence on Friday, October 18**. The congress encourages exchange and collaboration between all relevant disciplines and aims to bring together scientific and clinical research to bridge gaps in our understanding and management of central nervous system tumours. As part of our 30-year celebrations this year we will also be including reminders of EANO's achievements with memorabilia and special events.

During the congress, speakers from across the globe will present the latest clinical trial outcomes and highlight key advances in basic and translational science. **Key themes of the Glasgow 2024 meeting** include advanced therapies, novel targets, artificial intelligence and data sharing, and quality of life issues including fertility and pregnancy. With multiple sessions organized jointly with partner organizations, there is a strong emphasis on international and interdisciplinary collaboration.

Enjoy Europe's largest neuro-oncology congress with participants from all over the world and help us celebrate our 30<sup>th</sup> birthday!

Anthony Chalmers  
President EANO Meeting 2024

& Susan Short  
EANO President



### EANO Executive Board

**President:** Susan Short,  
United Kingdom

**President-Elect:** Michael Platten,  
Germany

**Past President:** Matthias Preusser,  
Austria

**Treasurer:** Roberta Rudà, Italy

#### Members:

Anna Berghoff, Austria

Anthony Chalmers, United Kingdom

Christian Mawrin, Germany

Emilie Le Rhun, Switzerland

Evangelia Razis, Greece

Giuseppe Minniti, Italy

Lena Rosenlund, Sweden

### EANO 2024 President

Anthony Chalmers, United Kingdom

### EANO Scientific Committee

**Chair:** Manuel Valiente, Spain

**Past-Chair:** Michael Platten, Germany

#### Members:

Anna Berghoff, Austria

Anna Golebiewska, Luxemburg

Anthony Chalmers, United Kingdom

Antonella Castellano, Italy

Asgeir Jakola, Sweden

Benedikt Hasselbalch, Denmark

Dieter Henrik Heiland, Germany

Estela Pineda Losada, Spain

Felix Sahm, Germany

Franziska Ippen, Germany

(Youngster Representative)

Giuseppe Minniti, Italy

Isabelle Ryden, Sweden

(NAC Representative)

Luca Tiberi, Italy

Pim French, The Netherlands

Susan Short, United Kingdom

Tareq Juratli, Germany

### EANO Congress Organiser

Scientific Management, Exhibition,  
Sponsorship, General Organisation and  
Logistics

WMA GmbH

Lydia Schnedl

Julian Piskula

T: +43 1 4051383-14

E: eano-meetings@eano.eu

W: www.eano.eu/eano2024

### EANO Office

Alissa McGregor

Anja Bunderla

c/o WMA GmbH

Alser Straße 4

1090 Vienna, Austria

T: +43 1 4051383-31

E: office@eano.eu

W: www.eano.eu



**EANO**  
EUROPEAN ASSOCIATION  
OF NEURO-ONCOLOGY

## THURSDAY OCTOBER 17, EDUCATIONAL DAY

	Educational Day Clinical track	Educational Day Basic Science track	Educational Day Nurses/AHPs track
Room/Level	M1 Level 1 Meeting Academy	ALSH Ground Level SEC Centre	M4 Level 1 Meeting Academy
08.30 - 09.50	<b>EDC01</b> Targeted therapy in Low Grade Gliomas	<b>EDB01</b> Brain Metastases	<b>EDN01</b> Radiotherapy and Patient's Profiles
09.50 - 10.00	TIME TO CHANGE ROOMS		
10.00 - 11.00	<b>EDC02</b> How I treat?	<b>EDB02</b> Neurons in carcinogenesis	<b>EDN02</b> Support needs of children and AYAs
11.00 - 11.30	COFFEE BREAK (HALL 5)		
11.30 - 13.00	<b>EDC03</b> Innovative trial design in neuro-oncology	<b>EDB03</b> Liquid biopsies	<b>EDN03</b> Managing neuro-psychiatric changes
13.00 - 14.00	LUNCH BREAK (HALL 5)		
14.00 - 15.20	<b>EDC04</b> Imaging	<b>EDB04</b> Precision medicine in neuro-oncology	<b>EDN04</b> Fear of Recurrence
15.20 - 15.30	TIME TO CHANGE ROOMS		
15.30 - 16.30	<b>EDC05</b> (incl. Nurse/AHPs track) Tumour Board	<b>EDB05</b> Preclinical to Clinical Translations	
16.30 - 17.00	TIME TO CHANGE ROOMS		
	EANO Meeting		
17.00 - 18.00	<b>OS01</b> Update on Response Assessment in Neuro-Oncology (RANO): projects and milestones	<b>JS01</b> EANO-EORTC: Current Studies of the EORTC Brain Tumor Group	<b>PC01</b> A clinical perspective on advanced molecular testing

## FRIDAY OCTOBER 18, EANO MEETING

Room/Level	Clyde Auditorium Ground Level SEC Armadillo	M1 Level 1 Meeting Academy	ALSH Ground Level SEC Centre	M4 Level 1 Meeting Academy
08.00 - 09.00	<b>ME01</b> Updates on cIMPACT-NOW	<b>ME02</b> Meet the Editors	<b>ME03</b> Patient and Public Involvement in Brain Tumor research	
09.00 - 09.15	TIME TO CHANGE ROOMS			
09.15 - 10.45	<b>JS02</b> EANO-ESTRO: DNA repair inhibitors in glioma	<b>KS01</b> Boosting immune responses in the brain	<b>OS02</b> Quality of Life and Symptom Management: state of the science	<b>WS01</b> EANO Career Boost Initiative: Leadership Skills & Knowledge Forum
10.45 - 11.15	COFFEE BREAK (HALL 5)			
11.15 - 11.45	Opening and Presidential Address			
11.45 - 13.15	<b>PL01</b> Brain connectome: implications for brain tumors and their treatments			
13.15 - 14.45	LUNCH BREAK (HALL 5)			
13.30 - 14.30		<b>CS01</b> Corporate Symposium	<b>CS02</b> Corporate Symposium	
14.45 - 16.15	<b>KS02</b> IDH inhibitors: clinical and molecular insights	<b>OS03</b> Exploiting dormancy, senescence and their links with the immune system in brain tumors	<b>OS04</b> Navigating fertility/pregnancy in patients with primary brain tumours	
16.15 - 16.30	TIME TO CHANGE ROOMS			
16.30 - 18.00	<b>JS03</b> EANO Youngsters-SIOP: Uniting frontiers against pediatric and adult brain tumors	<b>JS04</b> EANO-EANS: Clinical trials in surgical neuro-oncology	<b>PL02 (16.30-17.30)</b> Late Breaking Abstracts and EANO-SNO Scholarships	<b>WS02</b> EANO Youngsters Mentoring: Start of Something New
			<b>PP01 (17.30-18.00)</b> Poster Pitches I	
18.00 - 19.30	Poster Viewing with authors Group A (Hall 5)			

## SATURDAY OCTOBER 19, EANO MEETING

Room/Level	Lomond Auditorium Ground Level SEC Centre	M1 Level 1 Meeting Academy	ALSH Ground Level SEC Centre
08.00 - 09.00	<b>ME04</b> Adaptive Trials in Neurooncology	<b>ME05</b> Early diagnosis of glioma	<b>ME06</b> Lipid metabolism as a therapeutic target in glioblastoma
09.00 - 09.15	<b>TIME TO CHANGE ROOMS</b>		
09.15 - 10.45	<b>JS05</b> EANO-SNO: Translational Advances for Meningiomas	<b>OS05</b> Diagnosis, definition management, prevention, future research and radiation necrosis	<b>KS03</b> Breaking the walls: efforts to democratize access to clinical information
10.45 - 11.15	<b>COFFEE BREAK (HALL 5)</b>		
11.15 - 12.45	<b>OS06</b> Highlights from clinical abstracts	<b>OS07</b> Highlights from preclinical abstracts	<b>OS08</b> Advances in diagnosis and treatment of skull base tumors
12.45 - 14.15	<b>LUNCH BREAK (HALL 5)</b>		
13.00 - 14.00		<b>CS03</b> Corporate Symposium	<b>CS04 (13:00-13:30)</b> Corporate Symposium
14.15 - 15.45	<b>OS09</b> New target therapies in gliomas: TERT, ATRX, H3-K27M and TIM-3	<b>OS10</b> Symptomatic and asymptomatic brain metastasis: consensus and implications for therapy	<b>PC02</b> EANO Youngsters: Pro-cons discussions on clinical controversies
15.45 - 16.00	<b>TIME TO CHANGE ROOMS</b>		
16.00 - 17.00	<b>PD01</b> Neuro-Oncology Unplugged: A historic view on glioblastoma therapy - 30 years of EANO	<b>JS06</b> EANO-EANM: Therapy of meningioma	<b>WS03</b> EANO Youngsters: How to keep up with AI
17.00 - 17.15	<b>TIME TO CHANGE ROOMS</b>		
17.15 - 17.45	<b>PP02</b> Poster Pitches II		
17.15 - 18.45	<b>Poster Viewing with authors Group B (Hall 5)</b>		

## SUNDAY OCTOBER 20, EANO MEETING

Room/Level	Lomond Auditorium Ground Level SEC Centre	M1 Level 1 Meeting Academy	ALSH Ground Level SEC Centre
08.00 - 09.00	<b>EANO General Assembly</b>		
09.00 - 10.30	<b>KS04 Keynote Session</b> Molecular insights into oligodendrogliomas	<b>JS07 Joint Session</b> EANO-EACR: Navigating preclinical approaches to identify windows of opportunity and develop clinical trials	<b>OS11 Oral Session</b> Impact of variables from the host in neuro-oncology research
10.30 - 11.00	<b>COFFEE BREAK (HALL 5)</b>		
11.00 - 12.30	<b>KS05 Keynote Session</b> Cellular-based immunotherapies	<b>JS08 Joint Session</b> EANO-ESNR: Progress in MR imaging for brain tumor diagnosis and monitoring	<b>OS12 Oral Session</b> Efforts to improve management of incidental brain tumors
12.30 - 12.45	<b>Closing Remarks</b>		

## PROGRAMME CHANGES

All contents are as per date of printing (October 2, 2024).

The up-to-date scientific programme is available in the online programme on the congress website and in the congress app.

The organiser reserves the right to modify the programme in case of external or unforeseen circumstances and cannot assume any liability. No refunds can be granted in case of cancellations of speakers, lack of space in the conference room or any other incidents during the congress which are beyond the control of the organiser.

## LEGEND ABBREVIATIONS

JS	Joint Session
KS	Keynote Session
ME	Meet the Experts
OS	Oral Session
PC	Pro & Con Session
PD	Panel Discussion
PL	Plenary Session
WS	Workshop
CS	Corporate Symposium
PP	Poster Pitches



Full Programme

## SIDE MEETINGS

All Side Meetings are closed meetings. Information as per date of printing.

### THURSDAY, OCTOBER 17

Time	Meeting	Room/Floor
12.00 - 16.00	Telix Pharmaceuticals Advisory Board Meeting	Fyne / Ground Level SEC Centre
13.00 - 14.00	Biomarker Consortium	M2 / Level 1 Meeting Academy
15.30 - 16.30	EORTC Nuc Med Committee Meeting	M2 / Level 1 Meeting Academy

### FRIDAY, OCTOBER 18

Time	Meeting	Room/Floor
08.00 - 09.00	WFNOS Meeting	M2 / Level 1 Meeting Academy
13.15 - 14.15	EANO Educational Committee	M4 / Level 1 Meeting Academy
13.30 - 14.30	EANO/SNO/OUP Meeting	M2 / Level 1 Meeting Academy
14.30 - 15.30	RANO-leptomeningeal metastases	M4 / Level 1 Meeting Academy
18.00 - 19.00	EANO 2024 Meet the Industry Meeting	Mezzanine / Level 1 Meeting Academy
18.15 - 19.15	Study Group Annika Malmström	M2 / Level 1 Meeting Academy
18.15 - 19.15	Curevac Investigator Meeting	M4 / Level 1 Meeting Academy
20.00 - 22.30	Nurse & Allied Health Professional Dinner <i>Kindly supported by Novocure</i>	Browns Restaurant Glasgow Pick up point: SEC – outside the Armadillo on Congress Road

### SATURDAY, OCTOBER 19

Time	Meeting	Room/Floor
10.45 - 11.15	EANO Disparity Committee	M2 / Level 1 Meeting Academy
12.45 - 14.10	EANO SDM Working Group	M2 / Level 1 Meeting Academy
13.00 - 14.00	EANO Scientific Committee	M4 / Level 1 Meeting Academy
14.15 - 15.15	EANO Nurse & Allied Health Professional Committee (NAC)	M4 / Level 1 Meeting Academy
14.30 - 15.30	ETERNITY EORTC 1419	M2 / Level 1 Meeting Academy
17.15 - 18.15	National Societies Get-together	M4 / Level 1 Meeting Academy

## POSTER PRESENTATIONS

The posters have been divided into two separate poster viewing with authors sessions. Both poster numbers for both groups will be shown on the poster board. The first poster number indicates the poster presented during the first poster session on Friday, the second poster number indicates the poster presented during the second poster session on Saturday.

### SCHEDULE FOR DISPLAY, MOUNTING AND REMOVAL

#### Poster Viewing with authors Session I (Group A):

Friday, October 18, 18.00 - 19.30 hrs

- Posters will be on display on Friday, October 18
- Poster mounting: Friday, October 18 as of 07.30 hrs
- Poster removal: Friday, October 18 from 19.30 - 20.00 hrs

#### Poster Viewing with authors Session II (Group B):

Saturday, October 19, 17.15 - 18.45 hrs.

- Posters will be on display on Saturday, October 19
- Poster mounting: Saturday, October 19 as of 07.30 hrs
- Poster removal: Saturday, October 19 from 18.45 - 19.15 hrs

### POSTER TOPICS

- |   |  |
|---|--|
| 01. Tumor heterogeneity and plasticity                                    | 15. Multilayer diagnostics                                   |
| 02. Tumor microenvironment  | 16. Pediatric brain tumors                                   |
| 03. Cancer-Neuroscience   | 17. Brain metastasis and leptomeningeal disease              |
| 04. Metabolism  | 18. Adult glioma   |
| 05. DNA damage  | 19. Meningioma   |
| 06. New targets   | 20. Rare CNS tumors  |
| 07. Sex-related influence on brain tumors                                 | 21. Other tumor entities                                     |
| 08. Liquid biomarkers   | 22. QoL/Palliative care, end of life and care giving         |
| 09. Imaging strategies  | 23. Symptoms and symptom management                          |
| 10. Artificial intelligence/Machine learning/Computational neuro-oncology | 24. Patient and public involvement                           |
| 11. Connectome, functional neuro-oncology and cognition in brain tumors   | 25. Epidemiology/ Biobanks/ National registries              |
| 12. Immunotherapy   | 26. Preclinical neuro-oncology (not covered by other topics) |
| 13. Radiation technologies/Radiobiology/Radiotoxicity/Radiosensitizers    | 27. Clinical neuro-oncology                                  |
| 14. Advanced techniques in Neuro-Oncology (diagnosis and/ or treatment)   |  |

### ABSTRACTS

Abstracts presented at the EANO 2024 are available on the congress app, the congress website and in the October digital issue of the journal "NeuroOncology".

# EANO 2025 PRAGUE

Prague Congress Center • Prague, Czech Republic



## OVERVIEW OF CORPORATE SYMPOSIA

### FRIDAY, OCTOBER 18

Time	Title	Company	Room / Level
13.30 - 14.30	Multidisciplinary clinical management of diffuse glioma patients: Is it still the era of watch & wait?*	Servier	M1 / Level 1 Meeting Academy
13.30 - 14.30	Real World Evidence: 10 Years of Experience Treating High Grade Glioma with Tumor Treating Fields (TTFields) Therapy**	Novocure	Alsh / Ground Level SEC Centre

### SATURDAY, OCTOBER 19

Time	Title	Company	Room / Level
13.00 - 14.00	Development of IGv-001 for the treatment of newly diagnosed glioblastoma**	Imvax	M1 / Level 1 Meeting Academy
13.00 - 13.30	LITT* as a surgical minimally invasive treatment option in neuro-oncology (*Laser Interstitial Thermal Therapy)	Medtronic	Alsh / Ground Level SEC Centre

\*\*Lunch boxes will be provided to session attendees.



**ENROLLMENT COMPLETED**

~~NOW ENROLLING~~

Phase 2b study of IGv-001 in patients with newly diagnosed glioblastoma (NCT04485949)

Learn More: [www.clinicaltrials.gov/study/NCT04485949](http://www.clinicaltrials.gov/study/NCT04485949)  
[www.imvax.com/patients-families](http://www.imvax.com/patients-families)

**SPONSORS****Platinum Sponsor****Silver Sponsor****General Sponsors**

Carthera	Curevac
Focused Ultrasound Foundation	Novartis - Advanced Accelerator Applications International

**EXHIBITORS**

BRAIN UK	Cercare Medical
Chimerix	Dxcover
Fore Biotherapeutics	Medtronic
Novocure	SERB
Servier	Standard BioTools
Tessa Jowell Brain Cancer Mission	The Brain Tumour Charity
VectorBuilder	VPIX Medical
European Association of Neuro-Oncology (EANO)	

**GENERAL INFORMATION****Opening hours****Registration**

Hall 5, Ground Level SEC Centre

Wednesday, October 16, 2024	16.00 – 19.00 hrs
Thursday, October 17, 2024	07.30 – 18.30 hrs
Friday, October 18, 2024	07.30 – 19.00 hrs
Saturday, October 19, 2024	07.30 – 18.00 hrs
Sunday, October 20, 2024	07.30 – 11.30 hrs

**Speaker Service Centre**

M3, Level 1 Meeting Academy

Wednesday, October 16, 2024	16.00 – 19.00 hrs
Thursday, October 17, 2024	07.30 – 18.00 hrs
Friday, October 18, 2024	07.30 – 18.00 hrs
Saturday, October 19, 2024	07.30 – 17.00 hrs
Sunday, October 20, 2024	07.30 – 10.00 hrs

**Exhibition**

Hall 5, Ground Level SEC Centre

Thursday, October 17, 2024	09.30 – 17.30 hrs
Friday, October 18, 2024	09.00 – 19.30 hrs
Saturday, October 19, 2024	09.00 – 18.45 hrs
Sunday, October 20, 2024	CLOSED

**Poster Area**

Hall 5, Ground Level SEC Centre

Thursday, October 17, 2024	CLOSED
Friday, October 18, 2024	08.00 - 19.30 hrs
Saturday, October 19, 2024	08.00 - 18.45 hrs
Sunday, October 20, 2024	CLOSED

**Cloakroom**

Hall 5, Ground Level SEC Centre

Thursday, October 17, 2024	07.30 – 18.30 hrs
Friday, October 18, 2024	07.30 – 20.00 hrs
Saturday, October 19, 2024	07.30 – 19.00 hrs
Sunday, October 20, 2024	07.30 – 13.15 hrs





## Discover the clinical evidence of Optune Gio®

**VISIT BOOTH #11**

Optune Gio is a CE marked medical device (CE-0197).

### Indication

Newly diagnosed WHO grade 4 glioma.

Optune Gio is intended for the treatment of adult patients (18 years of age or older) with newly diagnosed WHO grade 4 glioma, following maximal debulking surgery or biopsy, radiation therapy and/or chemotherapy, concomitant with maintenance Temozolomide with or without Lomustine, and after systemic therapy is stopped.

### Contraindications

Do not use the Optune Gio treatment kit if you are pregnant, think you might be pregnant, or are trying to get pregnant. If you are a woman who is able to get pregnant, you must use birth control when using the device. The Optune Gio treatment kit was not tested in pregnant women.

Do not use the Optune Gio treatment kit if you have significant additional neurological disease (primary seizure disorder, dementia, Progressive degenerative neurological disorder, Meningitis or encephalitis, Hydrocephalus associated with increased intracranial pressure).

Do not use the Optune Gio treatment kit if you are known to be sensitive to conductive hydrogels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes. In this case, skin contact with the gel used with the Optune Gio treatment kit may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.

Do not use Optune Gio if you have an active implanted medical device, a skull defect (such as, missing bone with no replacement) or bullet fragments. Examples of active electronic devices include deep brain stimulators, spinal cord stimulators, vagus nerve stimulators, pacemakers and defibrillators. Use of the Optune Gio treatment kit together with implanted electronic devices has not been tested and may lead to malfunctioning of the implanted device. Use of the Optune Gio treatment kit together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render treatment ineffective.

The most common device specific adverse event was mild to moderate skin irritation under the arrays.

For more information on the indication, contraindications, warnings, notices and precautions, please read the product specific User Manual: <https://manuals.novocure.eu/>

### Location and Accessibility



#### Congress Venue

Scottish Event Campus | SEC

Glasgow G3 8YW

United Kingdom

[www.sec.co.uk/](http://www.sec.co.uk/)

#### WIFI

Network: EANO2024

Password: eano2024UK

#### Public transport

The SEC has its own dedicated railway station – Exhibition Centre – allowing easy access from the city centre and suburbs. There are six trains an hour (around every 10 minutes) from Glasgow Central station, departing from Platform 17 (low level). From Queen Street, you'll need to walk or get a bus to Central to continue your journey by train.

Strathclyde Passenger Transport operates the Glasgow Subway providing quick and convenient connections from 15 points across the city (the St. Enoch stop is a few minutes' walk from Central Station for onward transfer to the SEC).

Glasgow Conference Rover Ticket: Issued at a flat price of £5 at all ScotRail stations within the Conference Zone to conference delegates showing qualifying identification: conference badge OR registration confirmation with ID. The ticket is valid within Glasgow city centre for five days unlimited rail travel on all ScotRail services within the Conference Zone.

#### Glasgow

For information about Glasgow, visit the congress website: <https://www.eano.eu/eano2024/myconference/location-venue/#glasgow>

### Conference Policy

#### Badges

Admission to the congress (scientific sessions, exhibition and poster area) is only permitted to registered participants. Therefore, wearing your badge throughout the entire congress is mandatory!

#### Language

The official language of the congress is English (no simultaneous translation available).

**CME Credits**

The 19th Meeting of the European Association of Neuro-Oncology, Glasgow, United Kingdom 17/10/2024 - 20/10/2024, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **23.5** European CME credits (ECMEC@s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.



To **receive CME credits** participants must scan their **badge every day at the registration desk**. After completion of the post-congress survey sent by email, participants will be able to download their personalised certificate of attendance (incl. CME credits) and/or have it sent to their email address. The certificate of attendance will indicate the number of CME credits that correspond with the badge scans.

*Note: If a participant misses to scan the badge no credits will be accredited for that day.*

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at <https://edhub.ama-assn.org/pages/applications>. Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC@s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

**Certificate of attendance**

Confirmations of attendance will be issued via email to all participants after the congress.

**Catering**

During the morning **coffee breaks**, refreshments (coffee, tea and snacks) will be served free of charge to participants wearing name badges in the exhibition area.

During the **lunch breaks**, a light lunch as well as coffee and tea will be offered free of charge to participants wearing name badges in the exhibition area.

Additionally, water will be provided for free on all floors and coffee will be provided during the day in the exhibition area.

**Smoking Policy**

The EANO 2024 is officially a “no-smoking-congress”.

**Sustainability**

The EANO is committed to environmental sustainability, a responsible use of resources and sustainable congress materials. The organizer therefore asks you to keep these aspects in mind, e.g. by using public transport to get to the venue and networking events, bringing your own water bottle to the congress and by using the existing possibilities for waste separation.

**NEW****EANO****RESEARCH GRANT**

- Supporting high-quality projects in the field of neuro-oncology
- Available funding: up to 50,000 EUR
- Submission deadline: January 23, 2025

Learn more:

[www.eano.eu](http://www.eano.eu)

## NICE TO MEET YOU!

Please note that the number of participants for all networking events is limited and advance registration is mandatory for each event. Check ticket availability at the registration desk.

Admission will only be granted with a valid ticket. For the Welcome Reception and EANO Evening bring your congress badge to be scanned at the entrance.

### Welcome Reception - Civic Reception

**Location:** Glasgow Science Centre  
**Date:** Thursday, October 17, 2024  
**Time:** 18.30 – 21.00 hrs



Address: 50 Pacific Quay, Glasgow G51 1EA  
 4 minutes walking distance from the SEC  
*Individual arrival.*

Spend a nice networking evening with your colleagues in a relaxed atmosphere while enjoying finger food and drinks. The Civic Reception courtesy of The Rt Hon The Lord Provost of Glasgow and Glasgow City Council is free of charge, however admission is only possible for pre-registered participants.

Dresscode: casual

*The EANO acknowledges and is grateful for the support of the Lord Provost and the City Council of Glasgow.*



### Youngsters Networking Night

**Location:** Van Winkle West End  
**Date:** Friday, October 18, 2024  
**Time:** 20.00 - 24.00 hrs



Address: 23 Sandyford Pl, Glasgow G3 7NG  
 Public transport: Bus 3 or 77 station Elderslie Street or bus 100 station Argyle Street opp Berkeley Street  
*Individual arrival.*

Join the EANO Youngsters Networking Night and socialise with other young scientists. You can expect a relaxed atmosphere among other young colleagues from Europe and the world (age <36) with snacks and drinks (3 drinks are included in the price).

Dresscode: casual

*No sponsoring is used to fund any part of the evening.*

### Career Booster Initiative Networking

**Location:** The Exchange  
**Date:** Friday, October 18, 2024  
**Time:** 20:00-24:00 hrs



Address: 29 Royal Exchange Square, Glasgow, G1 3AJ

Public transport: Train stations Queen Street and Glasgow Central, Bus station Buchanan  
*Individual arrival.*

Join the excitement at the EANO Career Boost Initiative (CBI) social event! Tailored specifically for physicians and researchers striving for independence, this event is the perfect opportunity to forging meaningful connections and igniting fresh, innovative ideas. Highlighting the evening is an engaging workshop focused on enhancing your scientific communication skills, designed to turbocharge your networking potential. Tickets include free drinks and finger food.

Dresscode: casual

*Kindly supported by Ailse Oncology, Blue Earth Diagnostics, Nervianoms, Servier Nederland, TheraCryf*

### EANO Evening

**Location:** Kelvingrove Art Gallery & Museum  
**Date:** Saturday, October 19, 2024  
**Time:** 19.30 – 23.30 hrs



Address: Argyle St, Glasgow G3 8AG, United Kingdom  
 Public transport:

The bus stops at the front of Kelvingrove, on Argyle Street, have regular services from both directions. Services include: First Bus- services 2, 3 & 77; McGill's - service 17. The closest Subway station is Kelvinhall.  
*Individual arrival.*

Spend a wonderful evening with your colleagues and friends from around the world. You will be able to enjoy dinner and drinks together with music in an authentic atmosphere.

Dresscode: casual

*No sponsoring is used to fund any part of the evening.*

# SonoBird Trial

SonoCloud-9 in association with carboplatin vs standard-of-care in rGBM



RANDOMIZATION  
1:1

**FIRST RECURRENCE OF GBM**  
 ≥ 18 years age,  
 candidate for total or partial (≥ 50%) resection,  
 Enhancing tumor diameter ≤ 5 cm



- **EXPERIMENTAL ARM**  
SonoCloud-9 (SC9) and Carboplatin q3w
- **CONTROL ARM**  
Lomustine (CCNU) q6w or Temozolomide (TMZ) q4w


**DISEASE EVALUATION**




LEARN MORE




This pivotal, multi-site trial, conducted across Europe and the United States, is an open-label, randomized study aimed at evaluating and comparing survival outcomes in 560 patients. Participants, all candidates for resection, will either receive a SonoCloud® implant with repeated BBB opening in combination with carboplatin, or undergo standard-of-care chemotherapy. (NCT05902169)

[www.sonobird.eu](http://www.sonobird.eu)








- |                                     |                     |                  |             |                         |
|-------------------------------------|---------------------|------------------|-------------|-------------------------|
| 1 IBTA                              | 4 Cercare Medical   | 7 VPIX Medical   | 10 Servier  | 13 Chimerix             |
| 2 The Brain Tumour Charity          | 5 Standard BioTools | 8 BRAIN UK       | 11 Novocure | 15 Medtronic            |
| 3 Tessa Jowell Brain Cancer Mission | 6 Dxcover           | 9 Vector Builder | 12 SERB     | 16 Fore Biotherapeutics |

# The ACTION Study

Dordaviprone (ONC201) in newly diagnosed H3 K27M-mutant diffuse glioma



chimerix.com



- The H3 K27M mutation occurs in both pediatric and adult patients with glioma<sup>1,2</sup>
- Dordaviprone, a first-in-class imipridone, is a selective small molecule agonist of ClpP and antagonist of DRD2

The ACTION study (NCT05580562) is a randomized, double-blind, placebo-controlled, parallel-group international Phase 3 trial of patients with newly diagnosed, H3 K27M diffuse glioma after completion of radiotherapy.

### Eligibility Criteria

- H3 K27M-mutant diffuse glioma, H3 K27M mutation by IHC or NGS
- ≥10 kg body weight
- Completed radiotherapy within 2 to 6 weeks prior to randomization
- KPS/LPS ≥70
- Stable or decreasing corticosteroids and anti-seizure medication for seven days
- Not eligible: Spinal tumors, DIPG, leptomeningeal spread, CSF dissemination

1:1:1 Randomization (2–6 weeks post RT)

Dordaviprone (625 mg)  
Twice-weekly

Dordaviprone (625 mg)  
Once-weekly

Placebo

Eligibility will not be restricted based on age, provided patients are ≥10 kg. Patients ≤52.5 kg will receive a dose scaled by body weight.

### Primary Outcomes:

- Efficacy: OS, PFS

### Study Status:

- ACTION is enrolling at more than 140 centers throughout the USA, Europe, Israel, and Asia-Pacific, with additional sites planned.
- An up-to-date list of study sites is available at [clinicaltrials.gov](https://clinicaltrials.gov) (NCT05580562).
- Funding is available for eligible patients who must travel for treatment; contact [clinicaltrials@chimerix.com](mailto:clinicaltrials@chimerix.com) for more information.

Dordaviprone is an investigational drug currently undergoing clinical development and has not been approved for sale by regulatory health authorities.

### References

1. Lulla RR, et al. *Sci Adv.* 2016;2(3):e1501354
2. Khuong-Quang DA, et al. *Acta Neuropathol.* 2012;124(3):439-47

Visit us at Booth 13



30 YEARS OF EXCELLENCE



**#HappyBirthdayEANO**

**Leave your congratulations to EANO!**

What do you wish for the EANO?

What do you hope for the future of neuro-oncology?

Write to us in our guestbook on [www.30.eano.eu](http://www.30.eano.eu)  
or on social media and use *#HappyBirthdayEANO*.

We look forward to hearing from you!